Who are AZATHIOPRINE or METHOTREXATE's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azathioprine-or-methotrexate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AZATHIOPRINE or METHOTREXATE — Competitive Intelligence Brief

AZATHIOPRINE or METHOTREXATE (AZATHIOPRINE or METHOTREXATE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive agents / Antimetabolites. Area: Immunology / Rheumatology / Gastroenterology.

marketed Immunosuppressive agents / Antimetabolites Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) for azathioprine; Dihydrofolate reductase (DHFR) for methotrexate Immunology / Rheumatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

AZATHIOPRINE or METHOTREXATE (AZATHIOPRINE or METHOTREXATE) — Prof. Arie Levine. Azathioprine and methotrexate are immunosuppressive agents that inhibit cell proliferation and reduce immune activation by interfering with nucleotide synthesis and cellular metabolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AZATHIOPRINE or METHOTREXATE TARGET	AZATHIOPRINE or METHOTREXATE	Prof. Arie Levine	marketed	Immunosuppressive agents / Antimetabolites	Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) for azathioprine; Dihydrofolate reductase (DHFR) for methotrexate

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive agents / Antimetabolites class)

Prof. Arie Levine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZATHIOPRINE or METHOTREXATE — Competitive Intelligence Brief. https://druglandscape.com/ci/azathioprine-or-methotrexate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab